pemetrexed / Generic mfg.  >>  Phase 1
Welcome,         Profile    Billing    Logout  

61 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
pemetrexed / Generic mfg.
CIRIFOUR, NCT04452214: A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors

Checkmark From CIRIFOUR trial in combination with nadunolimab in patients with solid tumors
Feb 2022 - Feb 2022: From CIRIFOUR trial in combination with nadunolimab in patients with solid tumors
Completed
1b
19
US
CAN04, Pembrolizumab, Carboplatin, Pemetrexed
Cantargia AB
Carcinoma, Non-Small-Cell Lung, Urothelial Carcinoma, Malignant Melanoma, Head and Neck Squamous Cell Carcinoma
06/23
06/23
ACTRN12609000260224: Optimising regulatory T cell depletion with cyclophosphamide in combination with chemotherapy for enhanced anti-tumour immunity in patients with non-small cell lung cancer (NSCLC) and malignant mesothelioma (MM).

Recruiting
1
33
 
Sir Charles Gairdner Hospital, National Health and Medical Research Council (NHMRC)
Malignant Mesothelioma, Non small cell lung cancer
 
 
ACTRN12609000294257: CD-40 activating antibody (CP-870,893) in combination with cisplatin and pemetrexed in unresectable malignant mesothelioma: a phase Ib study

Completed
1
15
 
Sir Charles Gairdner Hospital, Pfizer Australia (research grant-in-aid for investigator initiated study)
unresectable malignant pleural mesothelioma
 
 
NCT06322693: A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

Recruiting
1
475
Europe, US, RoW
TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin
GlaxoSmithKline
Neoplasms
08/25
02/27
ChiCTR-TRC-11001850: A Study of Maintenance EGFR-TKI in Advanced lung adenocarcinoma patients after chemotherapy with different cycles

Completed
1
60
 
Pemetrexed with Cisplatin or Docetaxel with Cisplatin for 4 cycles ;Pemetrexed with Cisplatin or Docetaxel with Cisplatin for 2 cycles
Chinese PLA General Hospital; Chinese PLA General Hospital, Wu Jieping Medical Foundation
Lung Cancer
 
 
ChiCTR-TRC-14004696: Randomized study of first-line pemetrexed (Pe) plus platinum (P) followed by second-line docetaxel (D) versus first-line DP followed by second-line Pe in advanced non-small cell lung cancer

Recruiting
1
100
 
first-line pemetrexed (Pe) plus platinum (P) follo ;first-line DP followed by second-line Pe
The Affiliated Hospital of Guiyang Medical University/Guizhou Cancer Hospital; Level of the institution：, Sci-Tech Office of Guizhou Province
Lung cancer
 
 
ChiCTR1800016615: Efficacy and safety of intrathecal pemetrexed for treating leptomeningeal metastasis from lung adenoma cancer: Phase I clinical trial

Recruiting
1
20
 
intrathecal pemetrexed
The 2nd Affiliated Hospital of Harbin Medical University; The 2nd Affiliated Hospital of Harbin Medical University, self-raised
lung cancer
 
 
NCT04012619: Anlotinib Hydrochloride Combined With AP in Stage IIIB/IIIC/IV Non-squamous Non-small-cell Lung Cancer

Completed
1
8
RoW
Anlotinib Hydrochloride, Pemetrexed,cisplatin/carboplatin
Sichuan University, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Non-squamous Non-small-cell Lung Cancer, Anlotinib
11/19
12/20
ChiCTR1800019818: Single-center, open-label, prospective clinical study of pemetrexed monotherapy after pemetrexed in combination with lobaplatin in the treatment of advanced lung adenocarcinoma

Recruiting
1
60
 
Pemetrexe+Pemetrexe
The Fifth Affiliated Hospital of Sun Yat-sen University; Medical Ethics Committee of the Fifth Affiliated Hospital of Sun Yat-sen University, Self-raising
Advanced lung adenocarcinoma
 
 
NCT03307785: Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042

Active, not recruiting
1
58
US
Niraparib, Zejula, TSR-042, Carboplatin-Paclitaxel, Bevacizumab, Avastin, TSR-022, Carboplatin-Pemetrexed, Carboplatin-Nab-Paclitaxel
Tesaro, Inc.
Neoplasms, Metastatic Cancer, Advanced Cancer, Solid Tumor, Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer Stage IIIB, Non Small Cell Lung Cancer
02/20
08/24
CLOVER, NCT03509012: Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors

Hourglass Nov 2021 - Dec 2021 : From CLOVER trial in combination with tremelimumab for solid tumors
Active, not recruiting
1
105
Europe, Japan, US, RoW
Durvalumab, MEDI4736, Tremelimumab, Cisplatin (dose level 4), Cisplatin (dose level 3), Carboplatin (dose level 1), Carboplatin (dose level 2), Etoposide (dose level 1), Etoposide (dose level 2), Paclitaxel, Pemetrexed, External beam radiation (dose level 1), External beam radiation (dose level 2), External beam radiation (hyperfractionated), Cisplatin (dose level 1), Cisplatin (dose level 2), External beam radiation (standard)
AstraZeneca
Carcinoma, Squamous Cell of Head and Neck, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma
12/20
12/24
NCT03177291: Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC

Active, not recruiting
1
48
US
Pirfenidone, 5-methyl-1-phenyl-1H-pyridine-one, Esbriet, Carboplatin, Paraplatin, Paclitaxel, Abraxane, Pemetrexed, Alimta
H. Lee Moffitt Cancer Center and Research Institute
Lung Cancer, Non Small Cell Lung Cancer, Advanced Cancer, Metastatic Lung Cancer, Squamous Cell Lung Cancer, Non-Squamous Non-Small Cell Neoplasm of Lung
05/21
09/24
NSABP FC-10, NCT03626922: Study of Pembrolizumab With Pemetrexed and Oxaliplatin in Chemo-Refractory Metastatic Colorectal Cancer Patients

Active, not recruiting
1
33
US
Pembrolizumab, Keytruda, Pemetrexed, Alimta, Oxaliplatin, Eloxatin, Dexamethasone, Ozurdex, Folic Acid, Vitamin B-12
NSABP Foundation Inc, Merck Sharp & Dohme LLC, Eli Lilly and Company
Metastatic Colorectal Cancer
10/21
11/22
ChiCTR1900024164: Phase Ic clinical study for PEGylated Recombinant Human Endostatin Solution for Injection(M2ES) combined with pemetrexed disodium and carboplatin in patients with advanced non-squamous non-small cell lung cancer

Not yet recruiting
1
20
 
M2ES:15 mg/m2 ;M2ES:30 mg/m2 ;M2ES:45 mg/m2 ;M2ES:60 mg/m2 ;M2ES:Target dose
Sun Yat-sen University Cancer Center; Beijing Pu Luo Ji Pharmaceutical Technology Co., Ltd., Enterprise self-financing
non-squamous and non-small cell lung cancer
 
 
NCT03955042: Pemetrexed for the Treatment of Chordoma

Completed
1
15
US
Pemetrexed, Alimta
Saint John's Cancer Institute, Eli Lilly and Company, Chordoma Foundation
Chordoma
07/22
01/23
NCT03228537: Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma

Active, not recruiting
1
28
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG 7446, RG-7446, RG7446, RO 5541267, RO-5541267, RO5541267, Tecentriq, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Extrapleural Pneumonectomy, Pemetrexed Disodium, Alimta, Almita, LY231514, N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid Disodium Salt, Pleurectomy, Excision of Pleura, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation
National Cancer Institute (NCI)
Biphasic Mesothelioma, Epithelioid Mesothelioma, Stage I Pleural Malignant Mesothelioma AJCC v7, Stage IA Pleural Malignant Mesothelioma AJCC v7, Stage IB Pleural Malignant Mesothelioma AJCC v7, Stage II Pleural Malignant Mesothelioma AJCC v7, Stage III Pleural Malignant Mesothelioma AJCC v7
10/22
09/24
MAGELLAN, NCT03819465 / 2018-001748-74: A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC

Calendar Jan 2024 - Dec 2024: Data from MAGELLAN trial for 1L NSCLC
Active, not recruiting
1
175
Europe, US, RoW
Durvalumab, MEDI4736, Danvatirsen, AZD9150, Oleclumab, MEDI9447, MEDI5752, Pemetrexed, Carboplatin, Gemcitabine, Cisplatin, Nab-paclitaxel, AZD2936
AstraZeneca
Metastatic Non-Small Cell Lung Cancer (NSCLC)
05/23
03/26
NCT05459441: Efficacy and Safety Evaluation of Percutaneous Ommaya Capsule Injection of Autologous Bi-dimensional Specific T Cells in the Treatment of Glioma and in Combination With Pemetrexed in the Treatment of Brain/Meningeal Metastases

Recruiting
1
30
RoW
Autologous progenitor expansion -T, pemetrexed
Shanghai Pudong Hospital
Glioma, Brain Metastases
06/23
12/23
INDUCE-1, NCT02723955: Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors

Completed
1
829
Europe, Canada, Japan, US, RoW
feladilimab (GSK3359609), GSK3174998, Pembrolizumab, Docetaxel, Pemetrexed, Paclitaxel plus Carboplatin, Gemcitabine plus Carboplatin, Fluorouracil (5-FU) plus carboplatin or cisplatin, Dostarlimab, Cobolimab, Bintrafusp alfa
GlaxoSmithKline, Merck Sharp & Dohme LLC
Neoplasms
07/23
07/23
NCT05273814: Study of Chemotherapy and PD-1 Inhibitor Combination With Anti-angiogenesis to Treat Elderly Lung Cancer

Not yet recruiting
1
30
RoW
Tislelizumab, PD-1 inhibitor, Pemetrexed, Chemotherapy, Bevacizumab, Anti-angiogenesis
Tianjin Medical University Cancer Institute and Hospital
Non-Small Cell Lung Cancer
08/23
02/24
DIONE-01, NCT04328844: A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

Active, not recruiting
1
210
Europe
IOA-244, Avelumab Injection, Pemetrexed, Cisplatin, Ruxolitinib
iOnctura
Solid Tumor, Adult, Non-Hodgkin Lymphoma, Adult, NSCLC, Myelofibrosis, Uveal Melanoma
03/25
03/25
NCT04297605: Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2

Recruiting
1
28
US
Pembrolizumab, Pemetrexed (Chemotherapy), Nab-paclitaxel (Chemotherapy)
University of Rochester
Non-small Cell Lung Cancer
11/24
11/24
NCT02922764: A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer

Checkmark From a trial for solid tumors
Jun 2020 - Jun 2020: From a trial for solid tumors
Active, not recruiting
1
146
US
RGX-104, Ipilimumab, Docetaxel, Pembrolizumab, Carboplatin, Pemetrexed
Inspirna, Inc.
Endometrial Cancer, Endometrial Cancer Recurrent, Lung Cancer Recurrent, Lung Cancer, Non-small Cell Lung Cancer Metastatic, Non-small Cell Carcinoma
09/24
09/24
TQB2450-AL2846-I-01, NCT06116240: A Clinical Trial of TQB2450 Injection Combined With AL2846 Capsules in Patients With Advanced Solid Tumors

Active, not recruiting
1
135
RoW
TQB2450 injection, AL2846 capsule, Pemetrexed disodium for injection, Cisplatin injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Solid Tumor
12/23
12/23
IDE397-001, NCT04794699: Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion

Recruiting
1
180
Europe, US, RoW
IDE397, Docetaxel, Paclitaxel, Sacituzumab govitecan
IDEAYA Biosciences
Solid Tumor
12/26
03/27
NCT05136846: Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer

Recruiting
1
28
US
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Papaverine, Cerebid, Cerespan, Pavabid, Pavacap, Pavatym, Robaxapap, Radiation Therapy, Cancer Radiotherapy, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Pemetrexed, MTA, Multitargeted Antifolate, Pemfexy
Ohio State University Comprehensive Cancer Center
Locally Advanced Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
12/24
12/25
CHRYSALIS, NCT02609776: Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer

Checkmark From CHRYSALIS trial in 2L NSCLC at IASLC-WCLC 2020
Jan 2021 - Jan 2021: From CHRYSALIS trial in 2L NSCLC at IASLC-WCLC 2020
Checkmark Presentation of data from CHRYSALIS trial in combination with lazertinib for NSCLC at ESMO 2020
Sep 2020 - Sep 2020: Presentation of data from CHRYSALIS trial in combination with lazertinib for NSCLC at ESMO 2020
Checkmark From CHRYSALIS study in patients with advanced NSCLC at ASCO 2020
More
Active, not recruiting
1
751
Europe, Canada, Japan, US, RoW
Amivantamab, JNJ-61186372, Lazertinib, JNJ-73841937, YH25448, Carboplatin, Pemetrexed
Janssen Research & Development, LLC
Non-Small-Cell Lung Cancer
01/24
06/25
NCT06208033: SMET12 and Toripalimab Combined Chemotherapy in Patients With EGFR Positive Advanced Non-small Cell Lung Cancer (NSCLC)

Not yet recruiting
1
40
RoW
SMET12, toripalimab, Pemetrexed Disodium, Carboplatin, paclitaxel, cisplatin, Docetaxel
Fujian Cancer Hospital
EGFR Positive Non-small Cell Lung Cancer
10/24
12/24
NCT06431685: Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung Cancer

Recruiting
1
10
RoW
Whole Brain Low Dose Radiotherapy, WB-LDRT, Pemetrexed, Intrathecal Chemotherapy, Sintilimab, PD-1 Inhibitor, Chemotherapy, One of the standard chemotherapy regimens
Sichuan University
NSCLC, Low Dose Radiotherapy, PD-1 Inhibitor, Leptomeningeal Metastasis
05/26
12/26
AdvanTIG-105, NCT04047862: Study of Ociperlimab (BGB-A1217) in Combination with Tislelizumab in Advanced Solid Tumors

Checkmark Cohorts 1 & 2 data in combination with tislelizumab + chemotherapy from AdvanTIG-105 trial for squamous and non-squamous NSCLC at ESMO 2022
Sep 2022 - Sep 2022: Cohorts 1 & 2 data in combination with tislelizumab + chemotherapy from AdvanTIG-105 trial for squamous and non-squamous NSCLC at ESMO 2022
Completed
1
449
NA
Ociperlimab, Tislelizumab, Pemetrexed, Paclitaxel, Nab paclitaxel, Carboplatin, Cisplatin, Etoposide, 5fluorouracil, Oxaliplatin, Capecitabine
BeiGene
Locally Advanced and Metastatic Solid Tumors
08/24
08/24
NCT05504278: Efficacy and Safety of IBI351 in Combination With Sintilimab ± Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation

Recruiting
1
144
RoW
pemetrexed, cis-platinum, Sintilimab, IBI308, IBI351, GFH925, carboplatin
Innovent Biologics (Suzhou) Co. Ltd.
Advanced Non-Small Cell Lung Cancer
05/24
07/27
NCT06447662: A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

Recruiting
1
330
US
PF-07934040, PF-4040, Gemcitabine, Gemzar, Nab-paclitaxel, Abraxane, Cetuximab, Erbitux, Fluorouracil, 5-FU, 5-fluorouracil, Oxaliplatin, Eloxatin, Leucovorin, Folinic Acid, Wellcovorin, calcium folinate, Leucovorin Calcium, Bevacizumab, Zirabev, Avastin, Pembrolizumab, Pembro, Lambrolizumab, MK-3475, Keytruda, pemetrexed, Alimta, Cisplatin, Platinol, Cisplatinum, neoplatin, Paclitaxel, Taxol, Onxol, Carboplatin, Paraplatin, Stricarb
Pfizer
Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
06/27
06/28
NCT03715933: Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Recruiting
1
240
US
INBRX-109, Carboplatin, Cisplatin, Pemetrexed, 5-fluorouracil, Irinotecan, Temozolomide
Inhibrx, Inc.
Solid Tumors, Malignant Pleural Mesothelioma, Gastric Adenocarcinoma, Colorectal Adenocarcinoma, Sarcoma, Pancreatic Adenocarcinoma, Ewing Sarcoma, Chondrosarcoma, GIST, SDH-deficient Solid Tumors
12/25
07/26
ARC-4, NCT03846310: A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer

Hourglass Feb 2022 - Jun 2022 : Initial data from trial for NSCLC
Active, not recruiting
1
77
US, RoW
Etrumadenant, AB928, Zimberelimab, AB122, Carboplatin, Pemetrexed, Pembrolizumab
Arcus Biosciences, Inc., Gilead Sciences
Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer, Nonsquamous Nonsmall Cell Neoplasm of Lung, Sensitizing EGFR Gene Mutation
11/24
11/24
NCT06333951: AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol)

Recruiting
1
500
Japan, US, RoW
AMG 193, Carboplatin, Paclitaxel, Pembrolizumab, Pemetrexed, Sotorasib
Amgen
Thoracic Tumors, Non-small Cell Lung Cancer
06/29
06/32
NCT06607185: A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Not yet recruiting
1
750
NA
LY4066434., Cetuximab, Nab paclitaxel, Gemcitabine, Oxaliplatin, Leucovorin, Irinotecan, 5Fluorouracil, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab
Eli Lilly and Company
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor, Metastatic Solid Tumor
01/30
01/30
GO30103, NCT02794571: Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors

Active, not recruiting
1
518
Europe, Canada, Japan, US, RoW
Atezolizumab, MPDL3280A, RO5541267, Tecentriq, Tiragolumab, MTIG7192A, RO7092284, Carboplatin, Cisplatin, Pemetrexed, Paclitaxel, Etoposide, Capecitabine, Bevacizumab, Pembrolizumab
Genentech, Inc.
Advanced/Metastatic Tumors
10/24
10/24
MK-5890-001, NCT03396445: Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors

Checkmark Presentation of data from trial in combination with Keytruda in solid tumors at SITC 2019
Nov 2019 - Nov 2019: Presentation of data from trial in combination with Keytruda in solid tumors at SITC 2019
Active, not recruiting
1
202
Europe, US, RoW
Boserolimab, MK-5890, Pembrolizumab, MK-3475, Pemetrexed, ALIMTA®, Carboplatin, PARAPLATIN®, Nab-paclitaxel, ABRAXANE®
Merck Sharp & Dohme LLC
Pharmacokinetics, Solid Tumor, Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms
09/24
09/24
NCT06594874: A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors

Not yet recruiting
1
350
RoW
HS-10370, Adebrelimab, Cisplatin, Carboplatin, Pemetrexed
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Non-Small Cell Lung Cancer, Advanced Solid Tumors
10/26
01/27
AMBER, NCT02817633: A Study of TSR-022 in Participants With Advanced Solid Tumors

Hourglass Oct 2019 - Mar 2020 : From AMBER trial
Checkmark From AMBER trial at SITC 2018 [screenshot]
Nov 2018 - Nov 2018: From AMBER trial at SITC 2018 [screenshot]
Checkmark From AMBER trial in combination with TSR-022 at SITC 2018
Nov 2018 - Nov 2018: From AMBER trial in combination with TSR-022 at SITC 2018
Recruiting
1
447
Europe, US, RoW
TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin
Tesaro, Inc.
Neoplasms
04/25
04/27
NCT05911308: Abequolixron (RGX-104) and Durvalumab in Lung Cancer

Recruiting
1
24
US
Durvalumab, Imfinzi, Carboplatin, Paraplatin, Abequolixron, RGX 104, RGX-104, RGX104, SB-742881, Abraxane, Paclitaxel albumin-bound, Nab-paclitaxel, Pemetrexed, Alimta
UNC Lineberger Comprehensive Cancer Center, AstraZeneca, Rgenix, Inc.
Non-Small Cell Lung Cancer
12/25
12/26
NCI-2015-00693, NCT02419495: Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination with Multiple Standard Chemotherapy or Immunotherapy Agents in Patients with Advanced Malignancies

Terminated
1
221
US
Capecitabine, Ro 09-1978/000, Xeloda, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Eribulin, ER-086526, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Irinotecan Hydrochloride, Campto, Camptosar, Camptothecin 11, Camptothecin-11, CPT 11, CPT-11, Irinomedac, Irinotecan Hydrochloride Trihydrate, Irinotecan Monohydrochloride Trihydrate, U-101440E, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, Citrovorum Factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Nivolumab, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Olaparib, AZD 2281, AZD-2281, AZD2281, KU-0059436, Lynparza, PARP Inhibitor AZD2281, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Pemetrexed, MTA, Multitargeted Antifolate, Pemfexy, Selinexor, ATG-010, CRM1 Nuclear Export Inhibitor KPT-330, KPT-330, Selective Inhibitor of Nuclear Export KPT-330, SINE KPT-330, Xpovio, Topotecan, Hycamptamine, Topotecan Lactone
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Clinical Stage III Cutaneous Melanoma AJCC V8, Clinical Stage IV Cutaneous Melanoma AJCC V8, Fallopian Tube Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Ovarian Carcinoma, Pathologic Stage III Cutaneous Melanoma AJCC V8, Pathologic Stage IIIA Cutaneous Melanoma AJCC V8, Pathologic Stage IIIB Cutaneous Melanoma AJCC V8, Pathologic Stage IIIC Cutaneous Melanoma AJCC V8, Pathologic Stage IIID Cutaneous Melanoma AJCC V8, Pathologic Stage IV Cutaneous Melanoma AJCC V8, Primary Peritoneal Carcinoma, Stage III Lung Cancer AJCC V8, Stage III Renal Cell Cancer AJCC V8, Stage IIIA Lung Cancer AJCC V8, Stage IIIB Lung Cancer AJCC V8, Stage IIIC Lung Cancer AJCC V8, Stage IV Lung Cancer AJCC V8, Stage IV Renal Cell Cancer AJCC V8, Stage IVA Lung Cancer AJCC V8, Stage IVB Lung Cancer AJCC V8, Triple-Negative Breast Carcinoma, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Melanoma, Unresectable Renal Cell Carcinoma
09/24
09/24
NCT03760575: Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)

Recruiting
1
20
US
Pembrolizumab, MK-3475, Indocyanine Green (ICG) Image-Guided Surgery, Cisplatin, Pemetrexed
Abramson Cancer Center at Penn Medicine
Mesotheliomas Pleural
12/24
12/24
KEYVIBE-001, NCT02964013: Study of Vibostolimab Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001) ( )

Checkmark Data from part A of MK-7684-001 trial in combination with Keytruda for NSCLC at ESMO 2020
Sep 2020 - Sep 2020: Data from part A of MK-7684-001 trial in combination with Keytruda for NSCLC at ESMO 2020
Checkmark In combination with vibostolimab in advanced NSCLC at ESMO 2020
Sep 2020 - Sep 2020: In combination with vibostolimab in advanced NSCLC at ESMO 2020
Completed
1
470
NA
vibostolimab, MK-7684, pembrolizumab, KEYTRUDA®, MK-3475, pemetrexed, ALIMTA®, carboplatin, PARAPLATIN®, pembrolizumab/vibostolimab coformulation, MK-7684A, cisplatin, PLATINOL-AQ®, etoposide, ETOPOPHOS®
Merck Sharp & Dohme LLC
Neoplasms
07/24
07/24
CHRYSALIS-2, NCT04077463: A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer

Recruiting
1
460
Europe, Japan, US, RoW
Lazertinib, JNJ-73841937, Amivantamab, JNJ-61186372, Carboplatin, Pemetrexed
Janssen Research & Development, LLC
Carcinoma, Non-Small-Cell Lung
02/25
06/26
MK-0482-001, NCT03918278: A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors

Active, not recruiting
1
230
Europe, Canada, US, RoW
MK-0482, pembrolizumab, MK-3475, KEYTRUDA®, Paclitaxel, Nov-Onxol, Onxol, Paclitaxel Novaplus, Taxol, Nab-paclitaxel, Abraxane, Gemcitabine, Gemzar, Carboplatin, Paraplatin ®, Pemetrexed, Alimta
Merck Sharp & Dohme LLC
Neoplasms
02/25
02/25
FTIH, NCT03530397: A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors

Active, not recruiting
1
401
Europe, US, RoW
MEDI5752, Pemetrexed, Carboplatin, Pembrolizumab, Paclitaxel or Nab-Paclitaxel
MedImmune LLC
Selected Advanced Solid Tumors
12/25
12/25
ARC-25, NCT05891171: Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers

Recruiting
1
81
US, RoW
AB598, Zimberelimab, AB122, Carboplatin, Pemetrexed, Fluorouracil, Leucovorin, Oxaliplatin
Arcus Biosciences, Inc.
Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer (GEJ), Head and Neck Squamous Cell Carcinoma (HNSCC), Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Renal Cell Carcinoma (RCC), Triple Negative Breast Cancer (TNBC)
08/25
08/25
MK-4830-001, NCT03564691: Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors

Checkmark Data from a trial in combination with MK-4830 for solid tumor
Sep 2020 - Sep 2020: Data from a trial in combination with MK-4830 for solid tumor
Active, not recruiting
1
442
Europe, Canada, Japan, US, RoW
MK-4830, Pembrolizumab, MK-3475, SCH 900475, KEYTRUDA®, Carboplatin, Paraplatin, Pemetrexed, ALIMTA®, Pleumet, Pemecad, Lenvatinib, LENVIMA®, Lenvanix, Paclitaxel, Nov-Onxol, Onxol, Paclitaxel Novaplus, Taxol, Cisplatin, Platinol®, Platinol®-AQ, CDDP, MK-4830A
Merck Sharp & Dohme LLC
Neoplasms
09/25
09/25
NCT04162015: A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma

Active, not recruiting
1
22
US
Nivolumab, Pemetrexed, Cisplatin or Carboplatin
Memorial Sloan Kettering Cancer Center, Bristol-Myers Squibb
Malignant Pleural Mesothelioma
11/25
11/25
NCT02707666: A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma

Terminated
1
7
US
Pembrolizumab, Cisplatin and Pemetrexed
University of Chicago
Pleural Mesothelioma
04/23
04/23
DESTINY-Lung03, NCT04686305: Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

Calendar Jan 2024 - Dec 2024: Data from DESTINY LUNG03 trial for HER2+ non-squamous NSCLC
Recruiting
1
244
Europe, Canada, US, RoW
T-DXd, DS-8201a, Trastuzumab deruxtecan, Durvalumab, MEDI4736, Cisplatin, Carboplatin, Pemetrexed, Volrustomig, Other Name: MEDI5752, Rilvegostomig, Other Name: AZD2936
AstraZeneca, Daiichi Sankyo
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
12/25
12/25
ChiCTR2400082375: A Phase Ib Study on the Safety and Feasibility of Combined Therapy with Sildenafil, Tirelizumab, and Platinum-Containing Double Drugs as First-Line Treatment for Advanced Lung Adenocarcinoma

Not yet recruiting
1
10
 
Sildenafil in addition to tirelizumab and pemetrexed plus Carboplatin chemotherapy
Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital; Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, Self-funded
Advanced lung adenocarcinoma
 
 
NCT05298592: A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors

Completed
1
77
Europe, Japan, US, RoW
BMS-986406, Nivolumab, BMS-936558, Opdivo, Carboplatin, Pemetrexed, Paclitaxel
Bristol-Myers Squibb
Advanced Cancer
08/24
08/24
CodeBreak101, NCT04185883: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Checkmark Data from CodeBreak 101 trial in combination with panitumumab for colorectal cancer at ESMO 2022
Sep 2022 - Sep 2022: Data from CodeBreak 101 trial in combination with panitumumab for colorectal cancer at ESMO 2022
Checkmark Presentation of data from CodeBreak 101 tria in combination with Vectibix in KRAS G12C-mutated CRC at ESMO 2022
Sep 2022 - Sep 2022: Presentation of data from CodeBreak 101 tria in combination with Vectibix in KRAS G12C-mutated CRC at ESMO 2022
Checkmark Results from CodeBreak 101 study in combination with RMC-4630 at IASLC-WCLC
More
Recruiting
1
1200
Europe, Canada, Japan, US, RoW
Sotorasib, Trametinib, RMC-4630, Afatinib, Pembrolizumab, Panitumumab, Carboplatin, pemetrexed, docetaxel, paclitaxel, Atezolizumab, Palbociclib, MVASI® (bevacizumab-awwb), TNO155, IV Chemotherapy (Regimen 1), IV Chemotherapy (Regimen 2), BI 1701963, AMG 404, Everolimus
Amgen
Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
09/25
03/28
ChiCTR2400088658: Phase I clinical study of induction radiotherapy followed by neoadjuvant chemotherapy combined with Furmonertinib and adjuvant therapy with single-agent Furmonertinib for EGFR mutated resectable non-small cell lung cancer

Not yet recruiting
1
60
 
8Gy x Three times radiotherapy of peripheral primary focus 4Gy x Three times radiotherapy of central primary focus ; Pemetrexed 500mg/m2+ carboplatin AUC=5; D1, D22; Vometinib 80mg/ time orally, once a day, chemotherapy was started simultaneously, D1 ~ D49/56/63, until 1 week before surgery. Starting from 4 to 6 weeks after surgery, and no later than 8 weeks after surgery, continue to consolidate targeted therapy, orally once a day for 2 years
Jiangsu Cancer Hospital; Jiangsu Cancer Hospital, Self-raised
resectable stage IIA-IIIA non-small cell lung cancer
 
 
MK-1084-001, NCT05067283: A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors

Recruiting
1
830
Europe, Canada, Japan, US, RoW
MK-1084, Pembrolizumab, KEYTRUDA®, MK-3475, carboplatin, pemetrexed, cetuximab, oxaliplatin, leucovorin, 5-fluorouracil
Merck Sharp & Dohme LLC
Advanced Solid Tumors
08/26
08/26
MK-3475A-C18, NCT05017012: A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of MK-3475A (Pembrolizumab Formulated With MK-5180) In Advanced Solid Tumors

Active, not recruiting
1
72
Europe, Japan, RoW
MK-3475A, Pembrolizumab, Keytruda, MK-3475, Pemetrexed, Alimta, Carboplatin, Paclitaxel, Taxol, Nab-paclitaxel, Albumin-bound paclitaxel, Axitinib, Cisplatin, Platinol-AQ
Merck Sharp & Dohme LLC
Advanced or Metastatic Solid Tumors
09/26
09/26
ChiCTR2400080702: A prospective randomized controlled clinical study of pemetrexed intrathecal chemotherapy for neurotoxicity in patients with soft meningeal metastases of NSCLC treated with HGWD

Recruiting
1
100
 
Intrathecal pemetrexed via an Ommaya reservoir+ Oral HGWD; Intrathecal pemetrexed via an Ommaya reservoir
Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School; Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
lung cancer with leptomeningeal metastases
 
 
NCT04837716: Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer

Active, not recruiting
1
12
US
Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab awwb, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, Zirabev, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Ensartinib, X-396, Pemetrexed, MTA, Multitargeted Antifolate, Pemfexy
M.D. Anderson Cancer Center
Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
09/27
09/27
R2810-ONC-1622, NCT03233139: Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies

Checkmark From trial for advanced malignancies in Japanese patients at ASCO-SITC 2019 [screenshot]
Mar 2019 - Mar 2019: From trial for advanced malignancies in Japanese patients at ASCO-SITC 2019 [screenshot]
Recruiting
1
145
Japan
Cemiplimab, REGN2810, Libtayo, Ipilimumab, Platinum-doublet chemotherapy, Gemcitabine, Gemzar, Pemetrexed, Alimta, Paclitaxel, Taxol, Fianlimab
Regeneron Pharmaceuticals
Advanced Malignancies
12/27
03/30

Download Options